Background: Cyclic adenosine monophosphate (cAMP) dependent protein kinase A plays major role in cell signalling to undergo many cellular functions. Over expression of extracellular cAMP dependent protein kinase catalytic subunit alpha (PRKACA) causes severe tumorgenesis in prostate. Thus, computer aided high throughput virtual screening and molecular dynamics simulations studies were implemented to identify the potent leads for human PRKACA. Methods: The human PRKACA crystal structure was optimized in Maestro v9.2. Fifteen recently published PRKACA inhibitors were selected for compiling 5388 structural analogs from Ligand.Info database, these were prepared using LigPrep. Molecular docking from lesser to higher stringency towards minor steric classes was applied subsequently to the prepared ligand dataset into PRKACA active site using Glide v5.7. Molecular dynamics simulation studies were done using Desmond v3.0 to predict the activity of PRKACA-leptosidin complex. Results: Twenty lead molecules were identified. Lead-1 was observed to have relatively the least docking score compared to the identified lead molecules and 15 published inhibitors. The PRKACA-leptosidin complex deciphered that leptosidin blocked the active site residues Thr-51, Glu-121, Val-123, Glu-127 and Thr-183 directly through intermolecular hydrogen bonds. In molecular dynamics simulations, trajectory analysis also showed existence of water bridges between PRKACA and leptosidin. Conclusions: Docking and molecular dynamics studies revealed the better binding interaction of leptosidin with PRKACA. Leptosidin is having the better pharmacological properties thus it could be a futuristic perspective chemical compound for prostate cancer therapy.
INTRODUCTION
The human genome contains about 500 protein kinase genes. Protein kinases belong to tran ferase family, which get activated through phosphorylation reactions. The activated protein kinases regulate many biological processes like gene expression, signaling mechanisms, cell regulation and extra-intra cellular stimuli. 1 Mutations, halted cellular inhibition and overexpression or down regulation of protein kinases can result in acute diseases such as cancer, diabetes and deficiency in the immune system. 2, 3 Cancer is a result of tumorgenesis due to genetic and epigenetic alterations which lead to transformation of normal cells into malignant cells. Protein kinases have vital role in tumorgenesis and cell progression, hence, more than 70 kinase inhibitors are under clinical trials against cancer. 4 Most inhibitors of protein kinases were developed by targeting on the ATP binding site. [5] [6] [7] The cAMP (cyclic adenosine mono phosphate) dependent protein kinase catalytic alpha subunit (PRKACA) of protein kinase A (PKA) belongs to serine/threonine kinase family. The holoenzyme of human PKA has three types of catalytic subunits namely Cα Cβ, and Cγ [8] [9] [10] and four types of regulatory subunits RIα, RIβ, RIIα and RIIβ. [11] [12] [13] [14] In catalytic core motif, amino cleft involved in Mg-ATP binding site, where as carboxy cleft involved in peptide binding (regulator of C subunit activity) and catalysis. Activation of PKA depends on concentration levels of cAMP. Glucagon receptors bind with the Gproteins and the formed complex coupled with the adenylate cyclase becomes active to further act on ATP for release of cAMP. The released cAMP binds to regulatory subunits and results in free catalytic subunits. The free catalytic subunits can catalyse the transfer of ATP terminal phosphates to protein substrates at serine (or) threonine residues. PKAs are present in a variety of cells, acts on various substrates to participate in metabolism, 15 gene regulation, 16 cell growth and division, 17 cell differentiation, 18, 19 sperm motility 20 and ion channel conductivity, 21 among others. Thus, minute alteration in the catalytic subunit of PKA would hamper cell signalling mechanism leading to cancer. Experimental studies revealed that over expression of extracellular PKA catalytic subunit causes severe tumorgenesis in prostate cancer and other cancers. 22, 23 Therefore, PRKACA is being used as a drug target for various cancers. Quite a few inhibitors of PRKACA are under clinical trials. The present study was carried out for discovery of new class of PRKACA inhibitors with good pharmacokinetic properties using high throughput virtual screening and molecular dynamics simulations.
MATERIAL AND METHODS

Protein preparation
Co-crystal structure of human PRKACA with "796", an inhibitor was retrieved from the protein data bank (PDB). 24 The PRKACA structural features, active site residues and catalytic residues were analyzed using PDBsum 25 . Maestro v9.2 protein preparation wizard was used to fix erroneous atomic representations in crystal structure and its optimization.
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The bond orders were assigned to residues of proteins, hydrogen atoms were added and tautomeric states taking place at their normal pH (7.0) were generated. Protonation states of hydroxyl, histidine groups, "flips" of C/N atom and side chain O/N atom of the protein were optimized. Impref minimization was carried out using the OPLS ( 27 The ligands with poor pharmacological properties and reactive func tional groups were discarded applying Lipinski"s filter and reactive filter and an inhouse library of non-redundant, pharmacologically preferred conformations were prepared.
Computational docking
Docking is a procedure to predict the preferable binding orientation between the two molecules to form a stable complex. 38 Docking calculations were carried out using Glide v5.7. 29 The prepared and optimized ligands were flexibly docked in the grid box of the protein using MCSA (Monte Carlo based simulated algorithm) based minimization. Glide Score (GScore) was used for representing binding affinity and ranking. Three subsequent docking procedures such as high throughput virtual screening (HTVS), standard precision (SP) and extra precision (XP) 26,39 were implemented to retain lead molecules with better binding affinity in a good binding orientation without steric classes. 10,000 poses were generated during XP docking for each ligand and the best pose was retained after post docking minimization. The molecules which are docked favorably were ranked based on the XP Gscore.
Molecular dynamics
Molecular dynamics (MD) simulations for docking complex of human PRKACA -lead1 were performed using Desmond 3.2 40, 41 as implemented in Schrödinger package with 10 ns (nanoseconds) simulation time. The initial steps of MD simulations were performed by applying OPLS 2005 molecula mechanics force field. 27 Water molecules were placed to the ligand-receptor complex with simple point charge (SPC) water model. System was neutralized with counter ions, SHAKE algorithm 42 used to constrain the geometry of water molecules and heavy atom bond lengths with hydrogens, electrostatic interactions applied using particle mesh ewald (PME) method 43 and periodic boundary conditions (PBC) were used. 43 The full system of 44,164 atoms was simulated through the multistep MD protocols of Maestro v9.2. Briefly, full system minimization with restraints on solute was performed for maximum 2000 iterations of a hybrid of the steepest descent and the limited memory Broyden -Fletcher -Gold farb-Shanno LBFGS) algorithms, with a convergence threshold of 50.0 kcal/mol/Å. 2 Similar minimization without any restraints was performed with a convergence threshold of 5.0 kcal/mol/Å. 2 Non hydrogen solute atoms were restrained in the NVT ensemble (constant number of atoms N, volume V and temperature T) using 10 picoseconds (ps) simulation time and temperature of 10K. Simulations restraining non hydrogens solute atoms were performed in the NPT ensemble (constant number of atoms N, pressure P and temperature T) for 12 ps simulation time and temperature of 10K. Further, NPT ensemble for a simulation time of 24 ps restraining all nonhydrogen solute atoms (temperature 300K) and NPT ensemble, without restraints, for a simulation time of 24 ps (temperature 300K) was performed to relax the system. The relaxed system was simulated for a simulation time of 10000 ps with a time step of 2 femtosecond (fs), NPT ensemble using a Berendsen thermostat at 310 K and velocity resampling for every 1ps. Trajectories after every 4.8 ps were recorded. Energy fluctuations and RMSD of the complex in each trajectory were analyzed with respect to simulation time. The backbone and side chain root mean square fluctuations (RMSF) of each residue PRKACA were monitored for consistency. The inter-molecular interactions of lead1-PRKACA were assessed for stability of the docking complex.
RESULTS
Structural analysis of PRKACA
The co-crystal structure of PRKACA in complex with 796 24 provides novel insight to develop a new class of inhibitor designing. The protein is of 351 residues and comprises of 15 helices and 14 strands ( Figure 1A) . Asp166, Lys168, Glu170, Asn171 and Thr201 were reported as catalytic residues in catalytic site atlas (CSA) annotation ( Figure 1A) . The residues such as Leu49, Gly50, Thr51, Gly52, Gly55, Arg56, Ala70, Lys72, Ile73, Leu74, Val 103, Met120, Glu121, Tyr122, Val123, Asn171, Leu173, Thr183, Asp184 and Phe327 were localized to be in van der Waal contact with "796" constitute as the active site residue ( Figure 1A) .
PRKACA residues Leu49, Thr51, Gly52, Gly55, Arg56, Ala70, Lys72, Val104, Met120, Glu121, Tyr122, Val123, Asn171, Leu173, Thr183, Asp184 and Phe327 were involved in hydro phobic interactions with "796" ( Figure 1B ). The ligand "796" formed four H-bonds with the residues Glu121, Val123, Asn171 (catalytic residue) and Asp184 ( Figure 1B) . Further, assessments CASTp analysis supported the role of these residues to form binding pocket in human PRKACA.
Ligand dataset optimization
Compounds with similar structural geometry would deliver the similar effects; 29, 30 therefore, instead of implementing docking method to A small molecule databases directly, it is better to implement docking methods to a set of structural analogs for published inhibitors for identification of new class of inhibitors. Simplified molecular input line entry (SMILE) specification formats of 15. PRKACA published inhibitors were imported in to Ligand.info tool and 5388 structural analogues were obtained. The structural analogues were converted to their 3D structural forms. Multiple conformation generation of each analogue (3D structure Figure 1) . Among published inhibitors, balanol and "796" have showed the lowest XPG score of -10.63 Kcal/mol. Lead "1" (leptosidin) was found to have better XPG score than both balanol and hence "796" has better binding affinity compared to the existing PRKACA inhibitors.
PRKACA -leptosidin docking complex
The virtual screening result showed that, lept sidin (Supplementary Figure 2) had the lowest XPG score of -11.02 Kcal/mol (Supplementary Figure 1) compared to proposed leads and 15 published inhibitors. The good binding affinity of leptosidin is due to various interactions such as hydrogen bonding, hydrophobic interactions, hydrophilic interact tions, electrostatic interactions and steric inter actions. The PRKACA-leptosidin docked complex was visualized in Figure 2A and with residues involved in inter-atomic contact was shown in Figure 2B . Leptosidin was bound to PRKACA with five H (hydrogen)-bonds in addition to hydrophobic and van der Waal (vdW) interactions (Figure 2BThe Oxygen atom (10(O)) of leptosidin formed one H-bond with polar side chain hydrogen of Thr183 (2.439 Å). The residues Leu49, Gly50, Thr51, Gly52, Gly55, Arg56, Ala70, Lys72, Ile73, Leu74, Val103, Met120, Glu121, Tyr122, Val123, Asn171, Leu173, Thr183, Asp184 and Phe327 and Tyr336 were involved with good van der Waal interactions with leptosidin. Pharmacokinetic properties such as molecular weight, hydrogen bond donors, hydrogen bond acceptors, logP (water/octanol), water partition coefficient (QPlogPo/w), water solubility (QPlogS), permeability through Madin-Darb y Canine Kidney Cells (QPlogMDCK), Qik Prop predicted log IC50 value for blockage of K + channels (QPlogHERG), QikProp predicted gutblood barrier (QPPCaco), violations of the Lipinski"s rule of five (LROF), cell permeability (QPPCaco) etc. are critical for estimation of absorption and distribution of drugs within the body, drug metabolism and its access to biological membranes. All these values for leptosidin were well within the acceptable range for a drug with good pharmacological properties ( Table 1) .
Molecular dynamics simulations
Receptor structural rearrangements: Stability of PRKACA -leptosidin complex was evaluated through 10 ns molecular dynamic simulations. The simulations provided exact binding interaction of the docking complex with system embedded with water molecules, temperature and pressure. The complex of PRKACA-leptosidin was originated in all proper binding poses with an acceptable RMSD value (< 2 Å). RMSD values of the protein backbone atoms and the heavy atoms of inhibitor during the production phase relative to the starting structures were determined and plotted ( Figure 3A ). RMSD plot revealed that the complex was relatively stable throughout the simulation time. The overall RMSD range for backbone atoms were 0.6 -1.8 Å and heavy atoms were 0.7 -2.2 Å. The RMSF values of backbone and side chain atoms were assessed for each residue of PRKACA ( Figure 3B ). Side chain fluctuations of 90% of residues were observed within the range of 0.5 -2.0 Å; 94% of backbone residue fluctuations were within the range of 0.4 -1.5 Å. Side chain of Lys-319 showed a maximum fluctuations of 3 Å. Maximum backbone fluctuations up to 3 Å was observed for serine. Inhibitor binding pocket residues showed comparatively lower backbone and side chain fluctuations compared to other residues. The small range of RMSDs and RMSFs reflected slight structural rearrangement in the docking complex during simulation time. The energy plot showed that the energy of the system was relatively consistent during 10 ns MD simulations run ( Figure 3C ).
Interactions of PRKACA-leptosidin complex during simulations
The influence of lead1 on the dynamical properties of PRKACA active site have been clarified by analyzing the trajectory data obtained from the MD simulations. The PRKACA-leptosidin docking interactions were reproduced during the entire simulations period ( Figure 3D ). The analysis revealed crucial role of water molecules in PRKACAleptosidin interactions. In most of the trajectories, active site residues of PRKACA were involved in H-bonding through water bridges ( Figure 3D) . The Hbonds observed for Glu-121 and Val-123 in the PRKACA-leptosidin docking complex remained stable throughout the simulation period ( Figures 3D and 3E ). Glu-127 was observed to form H-bond with leptosidin till ~2000ps simulation time. In some trajectories Glu-127 formed H-bond with the one water bridge (supplementary Figure 3A) while in other trajectories it formed direct H-bonds with leptosidin (supplementary Figures 3B  and 3C ). Thr-51 was also forming hydrogen bonding d u r i n g M D simulations
(supplementary Figures 3B and 3F) Figure 2B ) were compared with crystallographic data of PRKACA-"796"complex ( Figures 1A and 1B) . Leptosidin is a flavonoid isolated from Coreopsis grandiflora. Favorable comparison of XPG score and binding orientations of leptosidin with the "796" and good pharmacokinetic properties revealed that it was better potential inhibitor for PRKACA than the existing inhibitors. Stability of docked complex was further analyzed through the molecular dynamic simulations using Desmond. 24, 25 The docking and MD simulations studies were revealed that the binding affinity of leptosidin towards PRKACA was highly stable with the proposed binding orientations. Analysis of RMSD, RMSF, potential energy and hydrogen bonding interactions of docking complex were rationalized that the steady nature of the lead compound. Active site residues such as Val-123 and Glu-121 residues have formed stable H-bond in all trajectories and complex was consistent ( Figure 3D) . Additional H-bonds (direct and water bridges) were observed with active site residues such as Leu49, Leu-172, Pro-169, Glu-170 and Tyr-330 during simulation time which revealed the PRKACAleptosidin complex as more stable in the physiological environmental conditions ( Figure 3D ). Finally, the docked result and MD simulations proved that leptosidin was having better binding orientations, RMSD, RMSF, potential energy and obey good pharmacological properties. Therefore it can be considered for designing drug molecules against prostate cancer.
